Investing.com -- Omeros Corporation (NASDAQ:OMER) stock rose 3.1% on Tuesday after the company announced it has completed its first commercial shipments of YARTEMLEA (narsoplimab-wuug) to distributors, with orders from transplant centers beginning immediately.
The company reported that both adult and pediatric patients with stem cell transplant-associated thrombotic microangiopathy (TA-TMA) are now receiving YARTEMLEA, including patients who recently failed prior off-label C5-inhibitor regimens, in both hospital and outpatient settings.
YARTEMLEA is the first and only FDA-approved therapy for TA-TMA, a potentially fatal complication of stem cell transplantation. The drug received FDA approval on December 23, 2025, for use in adults and children two years and older.
The medication works by selectively inhibiting MASP-2, the effector enzyme of the lectin pathway of complement, blocking the pathway’s activation while preserving classical and alternative complement functions important for infection defense.
TA-TMA can occur following both autologous and allogeneic hematopoietic stem cell transplantation, with higher prevalence after allogeneic transplant. According to the company, approximately 30,000 allogeneic transplants are performed annually in the United States and Europe, with recent studies estimating TA-TMA develops in up to 56% of allogeneic transplant recipients.
A marketing authorization application for YARTEMLEA is currently under review by the European Medicines Agency, with a decision expected in mid-2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
